15863210 Canada Inc. /
Fusion
AstraZeneca subsidiary to acquire Fusion Pharmaceuticals
What happened
15863210 Canada Inc., a wholly-owned subsidiary of AstraZeneca AB, agreed to acquire Fusion Pharmaceuticals Inc. for US$21.00 per share in cash, plus one contingent value right per share.
The contingent value right represents the right to receive a cash payment equal to US$3.00 per share, subject to the terms of the agreement.
The source
Everything on this page comes from the source below.
AstraZeneca subsidiary to acquire Fusion Pharmaceuticals
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly